# Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

> **NCT00452374** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 48 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Fludarabine
- **DRUG:** Oxaliplatin
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00452374
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00452374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00452374, "Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00452374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*